Health Blueprint

Back to Longevity News

News summary

First Parkinson’s patient dosed with USP30 inhibitor

Source: Longevity Technology • Published: 28 Oct 2026, 15:58

Summarized by Masters of Longevity from Longevity Technology.

Mission Therapeutics dosed the first patient with MTX325 to boost mitophagy.

First Parkinson’s patient dosed with USP30 inhibitor
Key Takeaways
  • MTX325 is an oral, brain-penetrant USP30 inhibitor.
  • The Phase 1b trial will enroll 36 mild-to-moderate Parkinson's patients.
  • Preclinical work showed increased mitophagy and neuron protection.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.